8-3-4 ⓔ文献
日本循環器学会・日本心不全学会，他：日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版)．2018.
Fonarow GC, Stough WG, et al: Investigators O–H and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE–HF Registry. J Am Coll Cardiol, 2007; 50: 768–777.
Nauta JF, Hummel YM, et al: What have we learned about heart failure with mid-range ejection fraction one year after its introduction? Eur J Heart Fail, 2017; 19: 1569–1573.
Bleumink GS, Knetsch AM, et al: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J, 2004; 25: 1614–1619.
Benjamin EJ, Muntner P, et al: Prevention Statistics C and Stroke Statistics S. Heart Disease and Stroke Statistics–2019 Update: A Report From the American Heart Association. Circulation, 2019; 139: e56–e528.
Heidenreich PA, Albert NM, et al: Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail, 2013; 6: 606–619.
Davie AP, Francis CM, et al: Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ, 1996; 312: 222.
Raymond I, Groenning BA, et al: The influence of age, sex and other variables on the plasma level of N–terminal pro brain natriuretic peptide in a large sample of the general population. Heart, 2003; 89: 745–751.
Mehra MR, Uber PA, et al: Obesity and suppressed B–type natriuretic peptide levels in heart failure. J Am Coll Cardiol, 2004; 43: 1590–1595.
Anwaruddin S, Lloyd–Jones DM, et al: Renal function, congestive heart failure, and amino–terminal pro–brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol, 2006; 47: 91–97.
Das SR, Drazner MH, et al: Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation, 2005; 112: 2163–2168.
Brownrigg J, Lorenzini M, et al: Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta–analysis. ESC Heart Fail, 2019; 6: 1041–1051.
van Deursen VM, Urso R, et al: Co–morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail, 2014; 16: 103–111.
日本循環器学会：循環器疾患診療実態調査報告書．2016.
Tsutsui H, Tsuchihashi–Makaya M, et al: Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J, 2006; 70: 1617–1623.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med, 1987; 316: 1429–1435.
Yusuf S, Pitt B, et al: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med, 1991; 325: 293–302.
Packer M, Fowler MB, et al: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation, 2002; 106: 2194–2199.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS–II): a randomised trial. Lancet, 1999; 353: 9–13.
Pitt B, Zannad F, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999; 341: 709–717.
Zannad F, McMurray JJ, et al: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11–21.
Masuyama T, Tsujino T, et al: Superiority of long–acting to short–acting loop diuretics in the treatment of congestive heart failure. Circ J, 2012; 76: 833–842.
Konstam MA, Gheorghiade M, et al: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA, 2007; 297: 1319–1331.
Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J, 2002; 66: 149–157.
Tsutsui H, Momomura SI, et al: Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure–J–SHIFT Study. Circ J, 2019; 83: 2049–2060.
Lund LH, Benson L, et al: Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA, 2012; 308: 2108–2117.
Liu F, Chen Y, et al: Effects of beta–blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS One, 2014; 9: e90555.
Pitt B, Pfeffer MA, et al: Spironolactone for heart failure with preserved ejection fraction. N Engl J Med, 2014; 370: 1383–1392.
Sorajja P, Mack M, et al: Initial experience with commercial transcatheter mitral valve repair in the United States. J Am Coll Cardiol, 2016; 67: 1129–1140.
Piepoli MF, Davos C, et al: Exercise training meta–analysis of trials in patients with chronic heart failure (ExTraMATCH). Bmj, 2004; 328: 189.
Cowie MR, Woehrle H, et al: Adaptive servo–ventilation for central sleep apnea in systolic heart failure. N Engl J Med, 2015; 373: 1095–1105.
Jones RH, Velazquez EJ, et al: Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med, 2009; 360: 1705–1717.
Ponikowski P, Voors AA, et al: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2016; 37: 2129–2200.